Related Experiment Video

Updated: Oct 9, 2026

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography
07:51

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography

Published on: September 22, 2011

Effects of canrenoate on red cell sodium transport and calf flow in essential hypertension

A Semplicini1, F Buzzaccarini, G Ceolotto

  • 1Clinica Medica I, University of Padua, Italy.

American Journal of Hypertension
|April 1, 1993
PubMed

Insights

Potassium canrenoate lowered blood pressure in hypertensive patients. This effect appears linked to blocking endogenous ouabain-like factors, impacting vascular resistance and red cell sodium balance.

Area of Science:

  • Cardiovascular Pharmacology
  • Hypertension Research
  • Renal Physiology

Background:

  • Essential hypertension is a complex condition affecting blood pressure regulation.
  • Endogenous ouabain-like factors are implicated in cardiovascular homeostasis.
  • Peripheral vascular resistance plays a key role in blood pressure management.

Purpose of the Study:

  • To investigate the effects of potassium canrenoate on blood pressure and vascular function in patients with essential hypertension.
  • To explore the role of endogenous ouabain-like factors in mediating canrenoate's effects.
  • To assess changes in red cell sodium homeostasis.

Main Methods:

  • A randomized, placebo-controlled study involving 15 patients with essential hypertension.
  • Administration of potassium canrenoate (100 mg/day) or placebo for 1 month.
  • Measurement of blood pressure, calf blood flow, calf vascular resistance, and red cell Na/K pump activity before and after ouabain challenge.

Main Results:

  • Potassium canrenoate significantly reduced blood pressure and the increase in calf vascular resistance following ouabain administration.
  • These effects were observed in a subset of patients, suggesting variable antagonism of endogenous ouabain-like factors.
  • Canrenoate enhanced red cell Na/K pump activity in patients where ouabain effects were antagonized.

Conclusions:

  • Potassium canrenoate effectively lowers blood pressure in essential hypertension.
  • The hypotensive effect of canrenoate may be partly mediated by antagonizing endogenous ouabain-like factors.
  • Canrenoate influences vascular resistance and red cell sodium balance, potentially through modulation of the Na/K pump.

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...